Inhibits acyl-CoA-1,2-diacylglycerol acyltransferase, esterification of higher fatty acids. Enhances peroxisomal β-oxidation of triglycerides in the liver.
A combined preparation containing polyunsaturated fatty acids of the omega-3 family - eicosapentaenoic acid, docosahexaenoic acid and vitamin E.
Has a therapeutic effect in the violations of lipid metabolism, due to severe hypertriglyceridemia, has anti-inflammatory effect. Promotes normalization of content low density lipoprotein and very low density lipoproteins, a change in the liquid properties of cell membranes, and an increase in the functional activity of membrane receptors, which improves the lipid-cellular interaction of lipoproteins with enzymes and the metabolism of lipoproteins. Antiaggregant effect of the drug is associated with the change under its influence of the lipid composition of cell membranes, including erythrocyte membranes,characterized by a decrease in the content of arachidonic acid in them and an increase in the level of eicosapentaenoic acid. As a result, there is a decrease in the synthesis of thromboxane A2 and other two-unsaturated eicosanoids (arachidonic acid derivatives) that enhance platelet aggregation and increase synthesis from eicosapentaenoic acid thromboxane A3 and other tri-unsaturated eicosanoids, which do not possess a proaggregant effect.
This complex of essential polyunsaturated fatty acids is used to normalize lipid metabolism and reduce the risk of developing atherosclerosis.
Vitamin E has antioxidant activity, participates in tissue respiration and other important processes of tissue metabolism; protects cells and tissues from the damaging effect of excessive amounts of free radicals and products of lipid peroxidation.